Elevated serum CD44, a transmembrane glycoprotein involving lymphocyte activation, adhesion, and migration, was correlated with the prognosis outcome in human non-Hodgkin lymphoma [24,25]. This evidence concerns the gene CD44 and non-Hodgkin lymphoma.